---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-24-000018"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2024-03-05T23:59:59+00:00"
generated_at: "2026-06-05T03:53:03.239501+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Gossamer Bio Q4/FY23 results: first PAH patient dosed in Phase 3 PROSERA, cash $296M into H1 2026

## Summary
- First PAH patient dosed in registrational Phase 3 PROSERA study; topline results expected Q4 2025.
- Japan PMDA accepted CTN, allowing inclusion of Japanese sites without PK bridging; could support Japanese NDA.
- Cash, equivalents & marketable securities $296.4M at Dec 31, 2023; expected to fund operations into H1 2026.
- Net loss for FY2023: $179.8M ($1.18 per share) vs $229.4M ($2.71) in FY2022.
- R&D expenses FY2023: $135.3M vs $170.9M in FY2022; G&A: $38.5M vs $47.6M.

## SEC filing metadata
- accession: 0001728117-24-000018
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2024-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811724000018/0001728117-24-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811724000018/goss-20240305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-24-000018
- JSON: https://secwatch.observer/filing/0001728117-24-000018.json
- Plain text: https://secwatch.observer/filing/0001728117-24-000018.txt

## Key facts
- Earnings Releases
  Gossamer Bio, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
  - Period: the fourth quarter and year ended December 31, 2023
  - Result: reported results
  source text: On March 5, 2024 , Gossamer Bio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter and fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728117/000172811724000018/0001728117-24-000018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.